Induction of bone ingrowth from acetabular defects to a porous surface with OP-1.
Reliable ingrowth of bone into porous-coated cementless total hip components can be expected in primary surgery. In the revision scenario, however, bone deficiency frequently is encountered and the remaining bone may have less ingrowth potential. Allograft bone and bone graft substitutes may be successful in healing bone defects, but have virtually no capacity to induce bone growth from the defect into the porous surface. To evaluate the role osteoinductive bone proteins may play in enhancing bone ingrowth, six canines had bilateral total hip arthroplasties with a cementless press-fit porous-coated acetabular component. A defect 8 mm in diameter and 5 mm in depth was created in the superior weightbearing area of each acetabulum. One defect in each animal was filled with recombinant human osteogenic protein-1. Each contralateral defect was filled with allograft bone, left empty (defect healing control), or no defect was created (intact) to serve as a control for ideal conditions for bone ingrowth. The osteogenic protein-treated defects healed more completely than allograft bone-treated or empty defects and achieved a bone density equivalent to the intact acetabulum. Bone ingrowth also occurred to a significantly higher degree in the osteogenic protein group compared with the allograft or empty defects achieving a degree of ingrowth equivalent to the intact acetabulum controls. The osteogenic bone protein was successful in achieving complete defect healing and inducing extensive ingrowth from the defect into the adjacent porous coating.
Barrack
Robert L
RL
Department of Orthopaedic Surgery, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-32, New Orleans, LA 70112, USA. rbarrack@tulane.edu
Cook
Stephen D
SD
Patrón
Laura Popich
LP
Salkeld
Samantha L
SL
Szuszczewicz
Edward
E
Whitecloud
Thomas S
TS
D000077:Acetabulum / Q000187:drug effects* / Q000254:growth & development*; D000818:Animals; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D004285:Dogs; D006622:Hip Prosthesis; D008297:Male; D016348:Osseointegration / Q000187:drug effects*; D011474:Prosthesis Design; D013499:Surface Properties; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta